SCHEMBL19984649

SCHEMBL19984649

Nc1cncc(C2CCC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 2/20 0.41
PDGFRB P09619 1/20 0.37
PDGFRA P16234 1/20 0.37
IRAK4 Q9NWZ3 1/20 0.36
KDM4E B2RXH2 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
DDO Q99489 1/20 0.35
BACE1 P56817 1/20 0.35
MAPT P10636 1/20 0.35
GSK3B P49841 1/20 0.35
PSMB5 P28074 1/20 0.34
TDO2 P48775 2/20 0.33
HRH2 P25021 1/20 0.33
HRH1 P35367 1/20 0.33
HRH4 Q9H3N8 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
NOS3 P29474 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24534027 0.96 CYP11B2 (0.46) CYP11B2PDGFRBPDGFRAIRAK4KDM4E
SCHEMBL14228280 0.91 KDM4E (0.38) CYP11B2PDGFRBPDGFRAKDM4EKMT2A
SCHEMBL2713555 0.82 CYP11B2 (0.41) CYP11B2
SCHEMBL30472838 0.80 CYP11B2 (0.59) CYP11B2PDGFRBPDGFRAKDM4EKMT2A
SCHEMBL23623126 0.80 HDAC4 (0.36) KDM4EKMT2AMEN1ALDH1A1LMNA
SCHEMBL23990304 0.75 CYP2A6 (0.53) CYP11B2PDGFRBPDGFRAMAPTGSK3B
SCHEMBL28092301 0.75 CYP11B2 (0.41) CYP11B2PDGFRBPDGFRAMAPTGSK3B
SCHEMBL4615341 0.75 LMNA (0.41) CYP11B2KDM4EKMT2AMEN1ALDH1A1
SCHEMBL24757849 0.73 MAPK1 (0.38) CYP11B2KDM4EKMT2AMEN1ALDH1A1
SCHEMBL30933201 0.73 MAPK1 (0.38) CYP11B2KDM4EKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410183-B2 Sars-cov2 main protease inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 US disclosed
US-20250042915-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2025-02-06 US disclosed
US-12091420-B2 SARS-COV2 main protease inhibitors GILEAD SCIENCES, INC. (US) 2024-09-17 US disclosed
US-20240239807-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2024-07-18 US disclosed
US-20240116946-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2024-04-11 US disclosed
EP-3512837-B1 PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 BOEHRINGER INGELHEIM INT (DE) 2020-07-22 EP disclosed
WO-2018052773-A1 PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250042915-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE CYP11B2 1461/4885PDGFRB 3504/4885PDGFRA 4232/4885
US-12091420-B2 SARS-COV2 main protease inhibitors ACE2, TMPRSS2, ACE CYP11B2 1461/4885PDGFRB 3504/4885PDGFRA 4232/4885
US-20240116946-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE CYP11B2 1461/4885PDGFRB 3504/4885PDGFRA 4232/4885
US-12410183-B2 Sars-cov2 main protease inhibitors ACE2, TMPRSS2, ACE CYP11B2 1461/4885PDGFRB 3504/4885PDGFRA 4232/4885
US-20240239807-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE CYP11B2 1461/4885PDGFRB 3504/4885PDGFRA 4232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.